Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.22.0.1
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Net sales   $ 269,276 $ 224,253 $ 526,995 $ 428,452
Operating income   62,348 50,995 125,570 100,087
Costs recognized on sale of acquired inventory       (1,596) (23)
Impact of partially owned consolidated subsidiaries(1)   8,114 130 8,748 130
Eminence impairment   (18,715) 0 (18,715) 0
Restructuring costs   (242)      
Corporate general, selling, and administrative expenses   (100,693) (83,116) (186,868) (155,714)
Diagnostics and Genomics [Member]          
Restructuring costs $ (1,200) (500)      
Operating Segments [Member]          
Operating income   104,161 88,560 201,725 167,584
Costs recognized on sale of acquired inventory   (84) (23) (1,595) (23)
Amortization of acquisition related intangible assets   (18,380) (15,027) (36,769) (30,528)
Impact of partially owned consolidated subsidiaries(1) [1]   1,004 207 2,567 207
Acquisition related expenses   13,262 (4,421) 15,618 (4,558)
Stock based compensation, inclusive of employer taxes   (14,815) (16,225) (28,675) (29,557)
Restructuring costs   (743) (142) (1,928) (142)
Operating Segments [Member] | Protein Sciences [Member]          
Net sales   204,971 172,179 402,156 326,625
Operating income   93,281 80,453 183,381 150,803
Operating Segments [Member] | Diagnostics and Genomics [Member]          
Net sales   64,527 52,469 125,512 102,595
Operating income   10,880 8,107 18,344 16,781
Intersegment Eliminations [Member]          
Net sales   (222) (395) (673) (768)
Corporate, Non-Segment [Member]          
Corporate general, selling, and administrative expenses   $ (1,334) $ (1,520) $ (1,524) $ (2,482)
[1] Adjusted operating income for the second quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted operating income.